Trophic factors therapy in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Progress in Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0079-6123(09)17514-3PMID 19660658PMCID PMC3430519
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial.

  2008cited by this paper
• Absolute requirement of GDNF for adult catecholaminergic neuron survival

  2008cited by this paper
• Dopaminergic neuroprotection by neurturin-expressing c17.2 neural stem cells in a rat model of Parkinson's disease.

  2007cited by this paper
• AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease.

  2007cited by this paper
• Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.

  2007cited by this paper
• Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.

  2007cited by this paper
• Striatal delivery of CERE‐120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys

  2007cited by this paper
• Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.

  2007cited by this paper
• Point source concentration of GDNF may explain failure of phase II clinical trial.

  2006cited by this paper
• Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease

  2006cited by this paper
• Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys

  2006cited by this paper
• Glial cell line–derived neurotrophic factor induces neuronal sprouting in human brain

  2005cited by this paper
• Intraputamenal infusion of glial cell line–derived neurotrophic factor in PD: A two‐year outcome study

  2005cited by this paper
• Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model

  2005cited by this paper
• Trophic factor distribution predicts functional recovery in parkinsonian monkeys

  2005cited by this paper
• Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.

  2004cited by this paper
• Novel functions and signalling pathways for GDNF

  2003cited by this paper
• Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease

  2003cited by this paper
• Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice.

  2003cited by this paper
• Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects

  2003cited by this paper
• Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD

  2003cited by this paper
• Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus).

  2003cited by this paper
• Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys.

  2002cited by this paper
• Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease

  2002cited by this paper
• Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector

  2002cited by this paper
• Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

  2002cited by this paper
• Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.

  2002cited by this paper
• alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

  2002cited by this paper
• Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

  2002cited by this paper
• α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease

  2002cited by this paper
• Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

  2001cited by this paper
• Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6‐OHDA lesion model depends on the site of administration of the trophic factor

  2000cited by this paper
• Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum.

  1999cited by this paper
• Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

  1999cited by this paper
• Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease

  1999cited by this paper
• Differential Effects of Glial Cell Line‐Derived Neurotrophic Factor and Neurturin on Developing and Adult Substantia Nigra Dopaminergic Neurons

  1999cited by this paper
• Localization of GDNF/neurturin receptor (c-ret, GFRα-1 and α-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum

  1999cited by this paper
• Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons

  1998cited by this paper
• Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy

  1998cited by this paper
• Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

  1998cited by this paper
• Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

  1997cited by this paper
• Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

  1997cited by this paper
• Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy

  1997cited by this paper
• GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

  1995cited by this paper
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper

• Nanotechnology-Based Advancements in Parkinson's Therapy: Exploring Animal Models and Clinical Insights in Neurodegenerative Disorders.

  2026cites this paper
• Novel Gene Therapy Approaches for Targeting Neurodegenerative Disorders: Focusing on Delivering Neurotrophic Genes

  2024cites this paper
• Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer’s Disease and Dementia with Lewy Bodies

  2022cites this paper
• Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer’s Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia

  2021cites this paper
• MMP-9 processing of intestinal smooth muscle-derived GDNF is required for neurotrophic action on enteric neurons.

  2020cites this paper
• GDNF-expressing Macrophages Restore Motor Functions at a Severe Late-stage, and Produce Long-Term Neuroprotective Effects at an Early-stage of Parkinson's Disease in Transgenic Parkin Q311X(A) Mice.

  2019cites this paper
• The multiple roles of exosomes in Parkinson's disease: an overview

  2019cites this paper
• Secretome of Undifferentiated Neural Progenitor Cells Induces Histological and Motor Improvements in a Rat Model of Parkinson's Disease

  2018cites this paper
• Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

  2018cites this paper
• Development of Dual Reconstituted Humanized Mice for Studies of HIV-1 Neuropathogenesis

  2017cites this paper
• Complementariness and Functional Parcellation of Neurotrophin Actions on the Oculomotor System

  2016cites this paper
• Noninvasive, Targeted, and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson’s Disease

  2016cites this paper
• Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease

  2016cites this paper
• Neuropharmacologic Approaches to Restore the Brain’s Microenvironment

  2016cites this paper
• Functional Diversity of Neurotrophin Actions on the Oculomotor System

  2016cites this paper
• Impact of the Secretome of Human Mesenchymal Stem Cells on Brain Structure and Animal Behavior in a Rat Model of Parkinson's Disease

  2016cites this paper
• Endogenous recovery after brain damage: molecular mechanisms that balance neuronal life/death fate

  2016cites this paper
• Progressive models of Parkinson's disease : behavioural and neurochemical analyses

  2015cites this paper
• TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.

  2015cites this paper
• A partial lesion model of Parkinson's disease in mice--characterization of a 6-OHDA-induced medial forebrain bundle lesion.

  2015cites this paper
• The Development of Treatment for Parkinson's Disease

  2015cites this paper
• Development of a Stereotaxic Device for Low Impact Implantation of Neural Constructs or Pieces of Neural Tissues into the Mammalian Brain

  2014cites this paper
• IGF-1 in autosomal dominant cerebellar ataxia - open-label trial

  2014cites this paper
• GDNF-Transfected Macrophages Produce Potent Neuroprotective Effects in Parkinson's Disease Mouse Model

  2014cites this paper
• Deficiency of GDNF Receptor GFRα1 in Alzheimer's Neurons Results in Neuronal Death

  2014cites this paper
• H2O2- or l-DOPA-injured dopaminergic neurons trigger the release of soluble mediators that up-regulate striatal GDNF through different signalling pathways.

  2014cites this paper
• Immunohistological analysis of neurturin and its receptors in human cochlea.

  2014cites this paper
• Bridging between transplantation therapy and neurotrophic factors in Parkinson's disease.

  2014cites this paper
• n-3 LCPUFA improves cognition: the young, the old and the sick.

  2014cites this paper
• Effect of glial cell line‐derived neurotrophic factor on behavior and key members of the brain serotonin system in mouse strains genetically predisposed to behavioral disorders

  2013cites this paper
• Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.

  2013cites this paper
• The Pharmacology of Regenerative Medicine

  2013influential citation
• Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

  2013cites this paper
• [Effect of GDNF on the behavior of ASC mice with high hereditary predisposition to catalepsy].

  2013cites this paper
• RESTORATION OF MOTOR AND NON-MOTOR FUNCTIONS BY NEUROTROPHIC FACTORS IN NONHUMAN PRIMATES WITH DOPAMINE DEPLETION

  2013cites this paper
• Molecular and Cellular Characterization of Dopamine Neuron Stimulating Peptides

  2013cites this paper
• Evidence for miR‐181 involvement in neuroinflammatory responses of astrocytes

  2013cites this paper
• Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

  2013cites this paper
• Mickael Decressac in Nigral Dopamine Neurons Induced Down-Regulation of Nurr 1 Disrupts GDNF Signaling −-Synuclein

  2012cites this paper
• Parkinson’s Disease: Insights from the Laboratory and Clinical Therapeutics

  2012cites this paper
• Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II

  2012cites this paper
• Alzheimer's disease: recent advances and future perspectives.

  2012cites this paper
• Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

  2012cites this paper
• Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications

  2012cites this paper
• The development of encapsulated cell technologies as therapies for neurological and sensory diseases.

  2012cites this paper
• α-Synuclein–Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons

  2012cites this paper
• Addressing Neurological Disorders With

  2011cites this paper
• Akt as a Victim, Villain and Potential Hero in Parkinson’s Disease Pathophysiology and Treatment

  2011cites this paper
• GDNF family ligands: a potential future for Parkinson's disease therapy.

  2011cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2011cites this paper
• Basic fibroblast growth factor promotes glial cell-derived neurotrophic factor gene expression mediated by activation of ERK5 in rat C6 glioma cells.

  2011cites this paper
• Commentary on chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Merja H. Voutilainen et al.

  2011cites this paper
• Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence.

  2011cites this paper
• The potential of neurotrophic factors for the treatment of Parkinson's disease

  2011cites this paper
• Pharmacological Enhancement of ex vivo Gene Therapy Neuroprotection in a Rodent Model of Retinal Degeneration

  2011cites this paper
• Dopamine Receptors, Motor Responses, and Dopaminergic Agonists

  2011cites this paper
• Neuroprotective Role of Dopamine Agonists: Evidence From Animal Models and Clinical Studies

  2011cites this paper
• GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

  2011influential citation
• Towards New Therapies for Parkinson's Disease

  2011cites this paper
• Differential expression of RET receptor isoforms in the olfactory system.

  2011cites this paper
• Principles of Translation of Biologic Therapies in Spinal Cord Injury

  2011cites this paper
• Addressing Neurological Disorders With Neuromodulation

  2011cites this paper
• GDNF and PD: Less Common Points of View

  2011cites this paper
• Analysis of mutations and the association between polymorphisms in the cerebral dopamine neurotrophic factor (CDNF) gene and Parkinson disease.

  2011cites this paper
• Cell transplantation and gene therapy in Parkinson's disease.

  2011cites this paper
• Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with l-dopa–induced dyskinesia

  2010cites this paper
• Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors

  2010cites this paper
• Macrophage-mediated GDNF Delivery Protects Against Dopaminergic Neurodegeneration: A Therapeutic Strategy for Parkinson's Disease.

  2010cites this paper
• Stem cell transplantation for neurometabolic and neurodegenerative diseases.

  2010cites this paper
• Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo.

  2010cites this paper
• Mesenchymal stem cells for the treatment of neurodegenerative disease.

  2010cites this paper
• Nerve Growth Factor Regulates the Firing Patterns and Synaptic Composition of Motoneurons

  2010cites this paper
• Microglia and neuroprotection: from in vitro studies to therapeutic applications.

  2010cites this paper
• Potential Therapeutic Strategies for Neurodegenerative Diseases

  2010cites this paper
• Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

  2010cites this paper
• Pharmacokinetics of intravitreal glial cell line-derived neurotrophic factor: experimental studies in pigs.

  2009cites this paper
• Recovery following anterior thalamic lesions.

  2009cites this paper